Abstract
Transdermal 17β-oestradiol administration (17β-E2), used mainly in menopausal women, allows a continuous 17β-E2 delivery through the skin into the systemic circulation, avoiding intestinal and hepatic passage. In order to explore whether transdermal 17β-E2 could be used for the induction of puberty, 17β-E2 patches with low dose delivery were administered in nine prepubertal girls with Turner syndrome (bone age >10.5 years) for a mean period of 2.2 years. Treatment schedule: 5 μg/day for 6–9 months, 10 μg/day for 6–9 months, 25 μg/day for long-term substitution; addition of cyclic gestagen p.o. after 18–24 months. Breast development started within 3 months of therapy and menstruation occurred after 2 years. Growth rate increased from 3.2 to 5.0 cm/year during the 1st year of therapy, height prediction did not change. Serum oestradiol (E2) and urinary E2 conjugates increased proportionally with 17β-E2 doses, serum oestrone (E1) rose much less. The possibility to imitate time course, clinical events and hormonal changes of normal puberty, the absence of adverse drug reactions and the excellent acceptance and easy mode of application suggest that transdermal 17β-E2 is optimally suited for hormonal substitution in girls with hypogonadism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- 17β-E2 :
-
17-β-oestradiol
- E1 :
-
oestrone
- E2 :
-
oestradiol
- FSH:
-
follicle stimulating hormone
- LH:
-
luteinizing hormone
References
Bailey N, Pinneau SR (1952) Tables for predicting adult height from skeletal age. J Pediatr 40:426
Bidlingmaier F, Knorr D (1978) Oestrogens, physiological and clinical aspects. In: Laron Z (ed) Pediatric and adolescent endocrinology; vol 4. Karger, Basel, pp 71–84
Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL (1986) Biologic effects of transdermal estradiol. N Engl J Med 314:1615–1620
Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford University Press, Stanford, California
Kastrup KW, Turner study group (1986) Growth and development in girls with Turner's syndrome during early therapy with low doses of estradiol. Acta Endocrinol (Copenhagen) [Suppl] 279:157–163
Kastrup KW, Turner study group (1989) Estrogen treatment in Turner syndrome. In: Rosenfeld RR, Grumbach MM (eds) Turner syndrome. Dekker, New York, pp 371–378
Largo RH, Prader A (1983) Pubertal development in Swiss girls. Helv Paediatr Acta 38:229–243
Prader A, Largo RH, Molinari L, Issler C (1989) Physical growth of swiss children from birth to 20 years of age. Helv Paediatr [Suppl] 52
Ross JL, Cassorla FG, Skerda MC, Valk IM, Loriaux DL, Gordon B, Cutler GB (1983) A preliminary study of the effect of estrogen dose on growth in Turner's syndrome. N Engl J Med 309:1104–1106
Ross JL, Long LM, Skerda M, Cassorla FG, Kurtz D, Loriaux DL, Cutler GB Jr (1986) Effect of low doses of estradiol on 6-month growth rates and predicted height in patients with Turner syndrome. J Pediatr 109:950–953
Schenkel L, Balestras J, Schmitt L, Shaw J (1985) Transdermal oestrogen substitution in the menopause. In: Prescott LF, Nimmo WS (eds) Rate control in drug therapy. Churchill Livingstone, Edinburgh, pp 294–303
Tanner JM (1962) Growth and adolescence, 2nd edn. Blackwell, Oxford
Tanner JM, Goldstein H, Whitehouse RH (1970) Standards for children's height at ages 2–9 years allowing for height of parents. Arch Dis Child 45:755
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Illig, R., DeCampo, C., Lang-Muritano, M.R. et al. A physiological mode of puberty induction in hypogonadal girls by low dose transdermal 17β-oestradiol. Eur J Pediatr 150, 86–91 (1990). https://doi.org/10.1007/BF02072044
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02072044